Navigation Links
Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Company's Latest Announcement
Date:5/19/2009

WOODMERE, N.Y., May 19 /PRNewswire/ -- The Quigley Corporation (Nasdaq: QGLY) announced yesterday that its Board was exploring various options, including hiring an investment banker and exploring "strategic alternatives".

Ted Karkus, Mark Burnett, John DeShazo, Mark Frank, Louis Gleckel, MD, Mark Leventhal, and James McCubbin ("the Shareholder Nominees") believe that the recent announcement is an 11th hour attempt to obtain shareholder votes and is further evidence of the need for a slate of new highly qualified directors to protect the interests of all shareholders.

"Shareholders should ask why the incumbents released this announcement just two days before the shareholder meeting," commented Mr. Karkus. "A responsible Board should always be reviewing the Company's strategic alternatives," he added.

Ask yourself if you want the same Board that managed the Darius/Innerlight sale last year to execute any further "strategic alternatives". The Darius/Innerlight division was sold for a mere $1 million just before it turned around in early 2008. Please read our last press release which summarizes some of the many facts that trouble us with that transaction.

And, finally, ask yourself why they didn't pursue these "strategic alternatives" when the Company's OTC division had increasing sales and increasing profits, instead of now, when the division is likely to be worth significantly less, given declining sales, increasing losses and a weaker environment for selling assets.

For more information on the actions by Quigley management that have necessitated this proxy contest and the Federal Court's decision to reject Quigley's claims against the Shareholder Nominees, shareholders should refer to our previous press releases and the court order which are available at

SOURCE Ted Karkus
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
2. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
3. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
4. Lab Series(R) Skincare For Men Spa Indulges the 2007 Primetime Emmy(R) Nominees at the Sofitel(R) Los Angeles
5. Erie Indemnity Announces Nominees for Board of Directors
6. LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees
7. Tennenbaum Encourages Shareholders to Vote the Blue Proxy for Tennenbaum Director Nominees at Online Resources Annual Meeting as Recommended by Riskmetrics/ISS and Proxy Governance
8. MMI Investments Issues Letter to Chemed Stockholders Illustrating the Superior Qualifications of the MMI Nominees
9. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
10. Americans United for Life Announces Legal Prospectus on Probable Supreme Court Nominees
11. Support Bristols Highly Qualified Independent Nominees for Advocat Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 2014 Physical fitness may buffer some of the adverse ... new study by researchers from the American Cancer Society, ... study appears in the journal Mayo Clinic Proceeding ... and obesity and blood markers associated with cardiovascular disease ... , Sedentary behavior has been linked to an increase ...
(Date:7/14/2014)... July 14, 2014 BCC Research ... SYNTHETIC BIOLOGY: GLOBAL MARKETS , the global ... nearly $11.9 billion in 2018, with a five-year ... products account for the fastest growing segment, with ... Synthetic biology-enabled products in the pharmaceutical/diagnostics, chemical, energy, ...
(Date:7/14/2014)... CA (PRWEB) July 14, 2014 The ... Group is now offering Lumineers and porcelain ... extensive procedures that require more preparation and greater loss ... porcelain tooth-shaped shells to conceal visible flaws on the ... Sabbagh-Fard work closely with patients to ensure they offer ...
(Date:7/14/2014)... Bronson Gray HealthDay Reporter ... research suggests that a faltering sense of smell might ... an inexpensive, low-tech smell test could spot who needs ... studies, the decreased ability to identify odors was associated ... to Alzheimer,s disease. "We,re trying to be able ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, 2014 (HealthDay ... health issues, but dementia isn,t one of them, according to ... delay dementia, the researchers found. "For those who had ... a later age of developing full-blown dementia compared to those ... Woodruff, an assistant professor of neurology at the Mayo ...
Breaking Medicine News(10 mins):Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3
... of gift-,givers, Valentine,s Day never fails to leave some people ... feel truly special. Of,course roses are the go-to gift that,s ... a new HD TV the best way to tell him, ... reason why gift certificates sales were,second only to clothing during ...
... the International Society for Cardiovascular Translational Research (ISCTR) ... the Journal of Cardiovascular Translational Research (JCTR). ... Inaugural Meeting of the International Society for Cardiovascular ... 2008 in San Diego, CA, USA. The ...
... Features Over 7,400 Furniture Products & Services, ... VWR International, LLC, a,global distributor of scientific ... new 2008-2010 Laboratory Casework and Technical,Furniture Catalog, ... for the research laboratory industry, including customers ...
... living near the World Trade Center had sleeplessness, other ... -- Direct exposure to the World Trade Center ... shows. , The study, by researchers at the Mount ... 116 children averaging about 4 years of age who ...
... Merrill Lynch,s Global Pharmaceutical Conference Feb. ... 5, 2008, ... it will host a conference call and live webcast on,Wednesday, Feb. 27, 2008, ... ended Dec. 31, 2007. The Company also will provide,an operational and integration update ...
... Coherent, Inc.,(Pink Sheets: COHR), today announced its slate ... proxy for the annual meeting scheduled for,March 19, 2008 ... The nominees include current directors Garry Rogerson, John,Ambroseo, John ... first-time,nominees Susan James and Clifford Press., Susan James ...
Cached Medicine News:Health News:Leading Network of Aesthetic Service Providers Offers Unique Gift Ideas for Valentine's Day 2Health News:Springer to publish new society journal in cardiology 2Health News:VWR International Publishes New Laboratory Casework and Technical Furniture Catalog 2Health News:VWR International Publishes New Laboratory Casework and Technical Furniture Catalog 3Health News:9/11 Exposure Linked to Behavior Trouble in Kids 2Health News:Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007 2Health News:Coherent Announces Director Slate for Upcoming Annual Meeting 2
(Date:7/14/2014)... Calif. , July 14, 2014  Mallinckrodt plc (NYSE: ... QCOR ) today announced that the registration statement on ... ("SEC") by Mallinckrodt plc on May 16, 2014 and amended ... of Mallinckrodt and Questcor that also constitutes a prospectus of ... statement on Form S-4 is available on the SEC,s EDGAR ...
(Date:7/14/2014)... 2014 BioAdaptives, Inc. (OTCBB:BDPT) is pleased to ... the roles of President and CEO of the Company.  ... the company that licensed its formulation, intellectual properties, and ... "Mr. Gerald Epling , who ... a privately held entity to a public company, has ...
(Date:7/13/2014)... , July 13, 2014  Eli Lilly ... announced results from its non-clinical study in genetically ... version of the beta-amyloid antibody N3pG and beta-secretase ... therapy was more effective in removing clumps of ... that is thought to lead to Alzheimer,s disease ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 2Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 4Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 6Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 7BioAdaptives Prepares for Next Step 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3
... Aug. 5, 2011 Varian Medical Systems, Inc. (NYSE: ... former CEO and member of the Board of Directors for ... of management in global medical device businesses, has been appointed ... Varian,s Board of Directors also increased its size from nine ...
... FOREST, Ill., Aug. 5, 2011 Hospira, Inc. (NYSE: ... today announced U.S. Food and Drug Administration (FDA) approval of ... presentations include 200 mg, 1 gm and 2 gm with ... sales of more than $750 million in 2010, led by ...
Cached Medicine Technology:Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 2Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 3
For Canalicular Stenosis. Non-traumatic tip. Silicone tubing swaged into probe. Note: Tubing securely swaged into malleable stainless steel probes. Medical grade silicone. Box of 3, sterile....
For proper plug sizing....
Contour Design Eyelid Implants....
For Frontalis Suspension in patients with significant ptosis and poor levator function....
Medicine Products: